CSL Behring
CSL Behring, an Australian-headquartered global leader and subsidiary of CSL, is one of the largest and most influential plasma therapy companies worldwide. The company operates through its integral segments: CSL Plasma, which manages a massive network of over 350 plasma collection centers across the US, Europe, and China, ensuring a reliable supply of raw material; and CSL Behring, which fractionates and distributes essential plasma-derived medicinal products to more than 100 countries. CSL Behring specializes in the development and manufacturing of plasma-derived and recombinant therapies primarily aimed at treating rare and serious diseases, including hemophilia, immunodeficiency disorders, and hereditary angioedema. Its extensive portfolio includes critical products like immunoglobulins, albumin, and specialty products for hematology and critical care. The company maintains its market leadership through substantial investments in R&D, consistently driving innovation in plasma fractionation technologies and setting high standards for product safety and efficacy. Recent developments, such as the FDA clearance for prefilled syringes of Hizentra, reinforce its commitment to patient-centric care and convenience, solidifying its position as a key global biotechnology company addressing various complex medical conditions.
Latest Market Research Report on Plasma Fractionation Download PDF Brochure Now
Grifols
Grifols, S.A. is a diversified global science and technology conglomerate based in Spain, dedicated to improving global health through its expertise in plasma-derived medicinal products and transfusion medicine. Grifols is consistently ranked as a leading player in the plasma fractionation market, dominating primarily through its Bioscience division. The company owns and operates one of the world’s largest integrated networks of plasma donation centers, processing approximately 25 percent of the global plasma supply across roughly 400 centers worldwide. This extensive collection network is crucial for maintaining a stable, global supply chain for its life-saving therapies. Grifols’ comprehensive portfolio focuses on essential components derived from plasma, including albumin, high-quality immunoglobulins, and clotting factors. The company provides innovative products and services to medical professionals in over 90 countries, specializing in treating patients with rare genetic diseases or severe infections. Strategic actions, such as the acquisition of plasma donation centers and international alliances (e.g., in Egypt), demonstrate Grifols’ ongoing commitment to expanding its capacity and geographical footprint to meet the growing clinical demand for plasma-based healthcare solutions.
Takeda Pharmaceutical Company Limited
Takeda, headquartered in Japan, is a global pharmaceutical powerhouse that has established itself as a pioneer in the plasma fractionation market, largely through its specialized immunology and rare disease divisions. The company significantly expanded its plasma capabilities following the strategic acquisition of Shire in 2019, gaining a formidable foothold in rare diseases and plasma-derived therapies. With decades of experience, Takeda delivers critical plasma-derived therapies targeting immune deficiencies and hereditary angioedema (HAE). Its global operations include over 200 plasma collection centers, which provide the raw material necessary for its manufacturing processes. Takeda is committed to sustainable plasma sourcing and expanding the global availability of treatments, leveraging its integrated collection and fractionation facilities worldwide. The company continually invests in research and development to enhance its product offerings, exemplified by receiving approvals for extended use of products like Hyqvia. Takeda’s enduring commitment positions it as a major industry leader driving innovation and accessibility in complex genetic analysis and plasma-based therapeutic solutions globally.
Octapharma AG
Octapharma AG, founded in Switzerland, is one of the largest privately-owned plasma product manufacturers globally, specializing in the development and production of human proteins for pharmaceutical use. The company has a strong focus across three key therapeutic areas: immunotherapy, hematology, and critical care. Octapharma manages over 180 plasma collection centers worldwide and operates multiple manufacturing and R&D facilities, adhering to rigorous standards of safety and efficacy in its plasma fractionation processes. The company is particularly recognized for its innovative approach to virus inactivation technologies, ensuring the highest quality of its plasma-derived products, which include immunoglobulins and clotting factors used to treat rare and chronic diseases. Its reputation for quality led to its appointment as the sole fractionator for the UK’s Plasma for Medicines Program in 2023. Octapharma’s dedication to providing a wide range of essential, high-quality plasma-derived products reinforces its importance as a key global provider meeting critical healthcare needs.
Kedrion Biopharma
Kedrion Biopharma is an Italy-based global biopharmaceutical company dedicated to the development and production of plasma-derived medicinal products. Kedrion focuses on collecting and fractionating human plasma to manufacture therapeutic products essential for treating chronic and rare diseases such as hemophilia, immunological disorders, and various infectious diseases. The company is noted for its leadership in the production of hyperimmune globulins. Kedrion maintains a strong international presence, especially in Europe, the U.S., and emerging markets, and actively strives to make therapies accessible in both developed and underserved regions. It frequently partners with national health systems, such as the Italian National Health System and the government of Portugal, to meet the demand for plasma-derived therapies and ensure affordability. Following its combination with Bio Products Laboratory (BPL), Kedrion has expanded its footprint and enhanced its capabilities in plasma collection and fractionation, positioning the combined entity as a major leader focused on developing innovative plasma products and strengthening its therapeutic portfolio.
Bio Products Laboratory Ltd. (BPL)
Bio Products Laboratory Ltd. (BPL) is a UK-based company specializing in the production of plasma-derived therapies, playing a crucial role in the immunology, hematology, and critical care sectors. BPL focuses on developing products essential for the treatment of bleeding disorders, primary immunodeficiencies, and other complex rare diseases. The company is recognized for its high standards in plasma processing and manufacturing, contributing significantly to the global supply of life-saving plasma products. BPL’s product portfolio includes immunoglobulins and coagulation factors, helping to address critical healthcare needs internationally. Recently, BPL combined with Kedrion Biopharma, a strategic move that significantly enhanced their collective global scale, plasma collection network, and manufacturing capabilities. This consolidation helps BPL leverage broader infrastructure and specialized R&D to continue focusing on the development and supply of vital plasma-derived biotherapies, reinforcing its position as a key contributor to the plasma fractionation landscape.
LFB Group
LFB S.A. (Laboratoire Français du Fractionnement et des Biotechnologies) is a major French biopharmaceutical group, established in 1994, that holds a significant position in the European market for biological medicines. The company is an expert in the manufacturing, development, and marketing of plasma-derived medicinal products (PDMPs) primarily used by health professionals in hospital settings to treat rare and serious diseases. LFB utilizes sophisticated bioproduction techniques in its plasma fractionation plants to extract and purify plasma proteins, delivering therapeutic products across three main segments: immunology, hemostasis (blood clotting), and intensive care. The group actively maintains a portfolio of over 15 products available in more than 30 countries. By concentrating its efforts on innovation and complex manufacturing processes, LFB ensures a consistent supply of essential plasma components, like immunoglobulins and coagulation factors, solidifying its status as a critical supplier within the European plasma fractionation industry.
Biotest AG
Biotest AG is a Germany-based global company specializing in the supply of plasma protein products and biotherapeutic drugs, operating under the control of Grifols. Biotest is a significant developer and manufacturer within the plasma fractionation industry, contributing a wide range of essential therapies focused on immunology, hematology, and intensive care medicine. The company is dedicated to utilizing human plasma to create medicines that treat life-threatening conditions, particularly immunodeficiencies and autoimmune disorders. Biotest’s product portfolio is highly regarded for its effectiveness and quality, benefiting from continuous R&D investment to enhance plasma yield and product safety. A recent milestone includes the FDA approval for Yimmugo, a treatment for primary humoral immunodeficiency, demonstrating Biotest’s ongoing commitment to developing next-generation plasma products. Through its comprehensive expertise and specialized focus areas, Biotest maintains its relevance and commitment to providing critical, high-quality biotherapeutic solutions across global markets.
Latest Market Research Report on Plasma Fractionation Download PDF Brochure Now